WHO Advises Against Remdesivir For Coronavirus Treatment

The anti-viral drug remdesivir should not be used to treat Covid-19 patients no matter how severe their illness as it has “no important effect” on survival chances, the World Health Organization said Friday.

Scratching one of the few treatments that had shown some initial promise in severe patients, a WHO Guideline Development Group (GDG) of international experts said there was “no evidence based on currently available data that it does improve patient-important outcomes”.

The United States, the European Union and other countries have granted temporary approval for the use of remdesivir after initial research showed it may shorten recovery time in some coronavirus patients.

US President Donald Trump was treated with remdesivir among other medicines after he tested positive for Covid-19 in October.

Friday’s WHO recommendation was based on four international randomised trials among more than 7,000 patients hospitalised with the virus.

Publishing updated treatment guidance in the BMJ medical journal, the panel acknowledged that their recommendation does not mean that remdesivir has no benefit for patients.

Comments

Post a Comment

Popular posts from this blog

Infosys Q3 results: 5 things to watch for tomorrow

Bengaluru: Another quarter and another downward revision in growth. Infosys Ltd is expected by at least three brokerages to scale down its full-year dollar revenue growth for the third time this year when India’s second-largest software firm declares its third quarter results on Friday. This is not surprising, considering the negative cross currency impact and also partially, on account of management’s inability to give a firm guidance. Still, 2015-16 is turning out to be roller-coaster ride for Infosys chief executive officer (CEO) Vishal Sikka. Till a year ago, Sikka seemed to have settled well and appeared to be enjoying his job (from playing cricket with employees in Mysuru to the after-results parties with senior management ranks). By December, Sikka came across as a different boss, unhappy with the progress made by the company, and heard telling his colleagues how he has been unable to implement things he had planned when he took over the current job in August 2014. I...
Read more

India to decide October-March borrowing at September 28 meeting: Finance Ministry source

Image
India will decide its October-March government borrowing amount on Thursday, a finance ministry official said on Tuesday. The government has said it will borrow 3.72 trillion rupees ($56.92 billion) via bonds during April-September, comprising 64 percent of its full-year borrowing. However, market participants expect the government to borrow more than the estimated amount in the second half of the fiscal year ending March, given its plans for fiscal stimulus to boost the economy which will entail higher-than-budgeted spending.
Read more

Dear millennial, do you need life insurance?

Image
Mumbai:  Smruti Valegaonkar, 25, Mumbai-based senior architect and product designer at MuseLab Design Engine, has a life insurance cover. “My parents bought it when I was a child,” said Valegaonkar, who has an endowment life insurance plan. The nominee of her insurance plan is her younger brother. “If she does not have dependence requirement, Valegaonkar can continue with the same plan,” said Suresh Sadagopan, founder of Ladder7 Financial Advisories. However, Valegaonkar wants to buy a separate life cover next year. Unlike Valegaonkar, Bhavika Maniar, 30, operations manager at Indiabulls Asset Management Co. Pvt. Ltd, does not have a life insurance cover. “This is the right time to buy because I have a stable monthly income now,” said Maniar. If you are in your 20s and 30s and, like Valegaonkar and Maniar, are considering buying a life insurance policy, here is what you should know: Do you need a life insurance policy? Life insurance is an instrument ...
Read more